Comparison · NCT02299414-e5bd5665
Anti-hypertensive Therapy to Goal <140/90 mmHg vs No Anti-hypertensive Unless BP is Severe (≥160/105 mmHg: Intraventricular Hemorrhage (IVH)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Anti-hypertensive Therapy to Goal <140/90 mmHg vs No Anti-hypertensive Unless BP is Severe (≥160/105 mmHg: Intraventricular Hemorrhage (IVH). Trial comparisons, record NCT02299414-e5bd5665. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02299414-e5bd5665
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.00911 | 0.00509 | 0.0162 | wilson | |
| Risk in group 2 | 0.0142 | 0.00886 | 0.0226 | wilson | |
| Risk difference, group 1 minus group 2 | -0.00506 | -0.0144 | 0.00382 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.643 | 0.302 | 1.37 | log | |
| Odds ratio, group 1 over group 2 | 0.639 | 0.298 | 1.37 | log | |
| Number needed to treat, for one fewer participant with the outcome on Anti-hypertensive Therapy to Goal <140/90 mmHg than on No Anti-hypertensive Unless BP is Severe (≥160/105 mmHg | 198 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Anti-hypertensive Therapy to Goal <140/90 mmHg | Labetalol or Nifedipine ER will be used as first-line to achieve goal; if necessary Nifedipine ER or Labetalol will be second-line antihypertensive. Rarely, other antihypertensive medications may also be used~Anti-hypertensive therapy: 1st line anti-hypertensive (Labetalol or Nifedipine ER) started; escalate to maximum dose and a preferred 2nd line medication if needed (nifedipine ER or Labetalol) | 11 | 1,208 | OG000 |
| Group 2 | No Anti-hypertensive Unless BP is Severe (≥160/105 mmHg | Antihypertensive therapy given only if BP becomes severe (defined as BP ≥160/105). The lowest dose of anti-hypertensive needed to keep blood pressure below this threshold will be given (1st-line - Labetalol or Nifedipine ER and 2nd-line - Labetalol or Nifedipine ER). Rarely other medications may be used~No anti-hypertensive therapy (unless BP is severe): Treatment will not be started if blood pressure remains \<160/105; for blood pressure ≥160/105, treatment with labetalol or Nifedipine ER will be initiated and maintained at lowest dose needed to keep blood pressure under 160/105. | 17 | 1,200 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- OTHER_PRE_SPECIFIED
- Title
- Intraventricular Hemorrhage (IVH)
- Description
- Incidence (%) with any IVH and with IVH Grades III and IV
- Time frame
- From delivery to hospital discharge (2 - 3 days after delivery)
- Population
Source ClinicalTrials.gov
Trial
- Title
- Chronic Hypertension and Pregnancy (CHAP) Project
- NCT number
- NCT02299414
- Phases
- PHASE4
- Conditions
- Hypertension
- Interventions
- Anti-hypertensive therapy, No anti-hypertensive therapy (unless BP is severe)
- Lead sponsor
- University of Alabama at Birmingham
- Results first posted
- 2023-05-17
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02299414?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02299414-e5bd5665